ArticleLeukemia2023
Validation of the imatinib-therapy failure model.
Abstract readLetter
In one paragraph
Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- ELTS score and early "warning" define a 2-stage risk framework for failure-free survival in chronic-phase CML.Blood advances · 2026Article
- Leukemia epidemiology in China: Burden, trends, and determinants in the 21st century.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Prognostic scoring systems in chronic myeloid leukaemia.Leukemia · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Xiaoshuai Zhang *Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.ORCID 0000-0001-5405-0802
Robert Peter Gale *Centre for Hematology Research, Department of Immunology and Inflammation, Imperial College London, London, UK.ORCID 0000-0002-9156-1676
Bingcheng Liu *National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Jian Huang *Department of Hematology, he First Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University, Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University, Zhejiang Provincial Clinical Research Center for Haematological Disorders, Zhejiang, China.
Yanli Zhang *Henan Cancer Hospital, The Affiliate Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xin Du *Division of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Guangdong, China.
Jianyu WengDepartment of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.ORCID 0000-0001-5446-292X
Weiming LiUnion hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, China.
Na XuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiaoli LiuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Chunyan ChenDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Hai LinDepartment of hematology, First Hospital of Jilin University, Jilin, China.
Guohui LiXi'an international medical center hospital, Shanxi, China.
Rong LiangDepartment of Hematology, Xijing Hospital, Airforce Military Medical University, Shanxi, China.
Zhuogang LiuShengjing Hospital of China Medical University, Shenyang, China.
Xiaodong WangSichuan Academy of Medical Sciences Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.
Yanqing ZhangDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Yanqiu HanThe affiliated hospital of Inner Mongolia Medical University, Inner Mongolia, China.ORCID 0000-0002-2658-0803
Chunshui LiuDepartment of Hematology, Cancer Center, The First Hospital of Jilin University, Changchun, China.
Jianda HuFujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fujian, China.ORCID 0000-0002-4438-2544
Lie LinDepartment of Hematology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Wei YangShengjing Hospital of China Medical University, Shenyang, China.
Zhenfang LiuDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Li MengDepartment of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Chuanqing TuDepartment of Hematology, Shenzhen Baoan Hospital, Shenzhen University Second Affiliated Hospital, Shenzhen, China.
Caifeng ZhengDepartment of Hematology, Shenzhen Baoan Hospital, Shenzhen University Second Affiliated Hospital, Shenzhen, China.
Zeping ZhouDepartment of Hematology, the Second Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.
Yanliang BaiDepartment of Hematology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China.
Huiying QiuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China.
Suning ChenNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China.
Fei LiCenter of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Jianxin GuoDepartment of Hematology, The Second Affiliated Hospital of Fujian Medical University, Fujian, China.
Zelin LiuDepartment of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital), Shenzhen, China.
Hui SunDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Li ZhouDepartment of Leukemia, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-9965-7533
Ru FengDepartment of Hematology, Beijing Hospital, National Center of Gerontology, Beijing, China.
Xiuli SunDepartment of hematology, The first affiliated hospital of Dalian Medical University, Dalian, China.
Xiaojun HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. huangxiaojun@bjmu.edu.cn.ORCID 0000-0002-2145-6643
Qian JiangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. jiangqian@medmail.com.cn.ORCID 0000-0001-7131-0522
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic AgentsHumansImatinib MesylatePyrimidinesAntineoplastic AgentsImatinib MesylatePyrimidines
Identifiers
PMID
36973351What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.